The scene of therapeutics for Niemann-Pick Disease Type C (NPC) is a dynamic one, with considerable strides being made in investigation. Several hopeful therapeutic methods are currently undergoing clinical trials, offering hope for patients living with this uncommon and deteriorating nervous system disorder. A mixture of drug-driven therapies and